These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30502777)

  • 1. Realizing the "Great Potential" of MCDA in HTA.
    Hall W; Mitton C; Levy A
    Value Health; 2018 Dec; 21(12):1355-1356. PubMed ID: 30502777
    [No Abstract]   [Full Text] [Related]  

  • 2. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could or Should We Use MCDA in the French HTA Process?
    Ghabri S; Josselin JM; Le Maux B
    Pharmacoeconomics; 2019 Dec; 37(12):1417-1419. PubMed ID: 31565761
    [No Abstract]   [Full Text] [Related]  

  • 4. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
    Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
    Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple criteria decision analysis for health technology assessment.
    Thokala P; Duenas A
    Value Health; 2012 Dec; 15(8):1172-81. PubMed ID: 23244821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion.
    Diaby V; Goeree R; Hoch J; Siebert U
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):13-9. PubMed ID: 25267699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of HTA research on policy decision-making.
    Youngkong S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A determination of topics for health technology assessment in Thailand: making decision makers involved.
    Lertpitakpong C; Chaikledkaew U; Thavorncharoensap M; Tantivess S; Praditsitthikorn N; Youngkong S; Yothasamut J; Udomsuk K; Sinthitichai K; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S100-9. PubMed ID: 19253492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.
    Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K
    Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Technology Assessment and Appraisal of Therapies for Rare Diseases.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Adv Exp Med Biol; 2017; 1031():221-231. PubMed ID: 29214575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AN INTEGRATED PERSPECTIVE ON THE ASSESSMENT OF TECHNOLOGIES: INTEGRATE-HTA.
    Wahlster P; Brereton L; Burns J; Hofmann B; Mozygemba K; Oortwijn W; Pfadenhauer L; Polus S; Rehfuess E; Schilling I; van der Wilt GJ; Gerhardus A
    Int J Technol Assess Health Care; 2017 Jan; 33(5):544-551. PubMed ID: 28756780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An introduction to the methods of cost-effectiveness analysis.
    Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge Translation in Practice: Exploring the Potential Use of MCDA in Central America and the Caribbean.
    Espinoza MA; Rojas R; Acosta de Patiño H
    Value Health Reg Issues; 2018 Dec; 17():148-149. PubMed ID: 30184512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective.
    Forster M; Pertile P
    Health Econ; 2013 Dec; 22(12):1507-14. PubMed ID: 23225192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Policy making and roles of health technology assessment.
    Tantivess S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S88-99. PubMed ID: 19253491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment for radiologists: basic principles and evaluation framework.
    Lim ME; O'Reilly D; Tarride JE; Burke N; Ferrusi IL; Campbell K; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):299-306. PubMed ID: 19394570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.
    Frederix GW; Haji Ali Afzali H; Dasbach EJ; Ward RL
    Pharmacoeconomics; 2015 Aug; 33(8):777-81. PubMed ID: 25827099
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence-based decision-making 3: Health technology assessment.
    O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.